{'fraction_non_alphanumeric': 0.025559105431309903, 'fraction_numerical': 0.003194888178913738, 'mean_word_length': 6.044943820224719, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Fluvoxamine-induced reversible euprolactinemic galactorrhea in a case of obsessive-compulsive disorder

Fluvoxamine is one of the commonly used selective serotonin reuptake inhibitors (SSRIs) as a first-line treatment for obsessive-compulsive disorder (OCD). Galactorrhea is a rarely observed adverse effect of SSRIs occurring through complex interactions between serotonergic and dopaminergic systems of brain. We report a case of fluvoxamine-induced reversible euprolactinemic galactorrhea in a 39-year-old woman after initiation of fluvoxamine for OCD. The patient's galactorrhea resolved on discontinuation of fluvoxamine.